{
  "validation_status": "PASS",
  "validation_confidence": 0.98,
  "missed_drugs": [],
  "grounded_search_performed": true,
  "search_results": [
    {
      "drug_queried": "Lucicebtide",
      "is_therapeutic_drug": true,
      "source_url": "https://clinicaltrials.gov/search?term=ST101",
      "source_title": "ClinicalTrials.gov - ST101",
      "evidence": "ST101 (Lucicebtide) is a first-in-class peptide antagonist of C/EBPÎ² being evaluated in patients with glioblastoma and other solid tumors.",
      "confidence": "high"
    }
  ],
  "issues_found": [],
  "checks_performed": {
    "hallucination_detection": {
      "passed": true,
      "note": "Lucicebtide is a valid therapeutic peptide (ST101) currently in clinical trials."
    },
    "omission_detection": {
      "passed": true,
      "note": "No other therapeutic drugs were identified in the title."
    },
    "rule_compliance": {
      "passed": true,
      "note": "Rule 9 was correctly applied: only the generic name 'Lucicebtide' was captured, excluding the code name 'ST101'."
    },
    "misclassification_detection": {
      "passed": true,
      "note": "Lucicebtide is correctly classified as Primary as it is the main agent being evaluated."
    }
  },
  "validation_reasoning": "1. Grounded search confirms Lucicebtide (ST101) is a real therapeutic agent (a peptide antagonist) used in glioblastoma research.\n2. The extractor correctly followed Rule 9 by capturing only the generic name 'Lucicebtide' and omitting the code name 'ST101' provided in parentheses.\n3. Mechanism of action terms ('antagonism') and biological processes ('mesenchymal cell transition') were correctly excluded per Rule 23.\n4. No other drugs or comparators are present in the title.\n5. The extraction is accurate and compliant with all provided rules."
}